Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy

Acute Lymphocytic Leukemia Clinical Trial

Official title:

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy: A Phase 2, Open-label, Single-arm, Single-center Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05456698
• Other study ID #: IIT2022011-EC-2
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: August 1, 2022
• Est. completion date: June 30, 2025

Study information

• Verified date: March 2022
• Source: Institute of Hematology & Blood Diseases Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A single-center, single-arm, open-label, interventional, phase II clinical trial to evaluate the efficacy and safety of InO in B-ALL achieved CR/CRi after 1L induction chemotherapy with positive minimal residual disease.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 31
• Est. completion date: June 30, 2025
• Est. primary completion date: July 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. New diagnosed B-ALL in hematologic complete remission (CR) after 1L induction chemotherapy with MRD positive. Molecular disease or MRD is defined by a value of at least of 10-4 (0.01%) by multicolor flow cytometry.

2. Age =18 years

3. ECOG PS score: 0 to 2

4. Functions of the main organs are normal, if the following criteria are met:

1. Total bilirubin (BIL) = 1.5 × upper limit of normal (ULN)

2. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) = 2.5 × ULN

3. Serum creatinine = 1.5 × ULN

4. Creatinine clearance = 30 ml/min

5. No active or co-existing malignancy with a life expectancy of less than 12 months

6. Patients are voluntarily enrolled into the study and have good compliance, and the Informed Consent Form (ICF) needs to be signed.

Exclusion Criteria:

1. Mixed lineage leukemia

2. Clinically significant liver disease such as history of veno-occlusive disease (VOD)/ sinusoidal obstruction syndrome (SOS)

3. Patients with severe and / or uncontrolled diseases, such as:

1. Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months before randomization, severe uncontrolled arrhythmias; uncontrolled blood pressure (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg)

2. Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis

3. Known to be human immunodeficiency virus positive (HIV+)

4. Active and uncontrolled disease/infection as judged by the treating physician

5. Active central nervous system (CNS) or extramedullary disease

6. Patients who have other malignant tumors at the same time; patients who are evaluated by the investigator to have concomitant diseases that seriously endanger the safety of the patients or affect the patients to complete the study

4. Pregnant or nursing women

5. Unable or unwilling to sign the consent form

6. Monoclonal antibodies therapy within 2 weeks before study entry

7. Radiotherapy or cancer chemotherapy (except for induction chemo) or any investigational drug within 2 weeks before study entry

8. Patients who have severe allergies (= grade 3) to active ingredients and any excipients of InO

9. Patients in other situations who are evaluated by the investigator to be ineligible

Related Conditions & MeSH terms

• Acute Lymphocytic Leukemia
• Neoplasm, Residual
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Drug:
• Inotuzumab ozogamicin
Patients who achieved CR/CRi had their InO dose at 1.5mg/m2 per cycle (28days/cycle), with 0.5mg/m2 administered on days 1, 8, and 15. Patients received treatment for up to two cycles in the absence of disease progression or unacceptable toxicity.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Institute of Hematology & Blood Diseases Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MRD negativity rate within the first treatment cycle	MRD negativity is defined as no presence of small numbers of leukemic cells detected by the flow cytometry after remission	At the end of Cycle 1 (each cycle is 28 days)
Secondary	Complete MRD response rates	Complete MRD response is defined as no presence of small numbers of leukemic cells detected by the flow cytometry after remission	At the end of Cycle 1 and Cycle 2, respectively (each cycle is 28 days)
Secondary	Duration of MRD negativity rate	The duration of MRD response was analyzed as the time from onset of MRD negativity until MRD or hematological relapse or date of last confirmation of negative MRD status.	From enrollment to the end of Cycle 1 or Cycle 2, which achieves MRD negative first (each cycle is 28 days)
Secondary	MRD level variation from baseline to post cycle 1, cycle 2 in patients with detectable MRD, respectively	The variation of MRD level from baseline to post cycle 1, cycle 2, respectively	From enrollment to the end of Cycle 1 and Cycle 2, respectively (each cycle is 28 days)
Secondary	Relapse-free Survival (RFS)	RFS is defined as the time from the date of CR until the date of relapse or death	Up to 5 years from enrollment
Secondary	Overall Survival (OS)	OS is defined as the time from enrollment to date of death due to any cause.	Up to 5 years from enrollment